Droloxifene

Summary

Droloxifene (CHEMBL487) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 387.5 Da · C26H29NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL487
Name	Droloxifene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3033767
Molecular formula	C26H29NO2
Molecular weight	387.5
InChIKey	ZQZFYGIXNQKOAV-OCEACIFDSA-N

SMILES: CC/C(=C(/C1=CC=C(C=C1)OCCN(C)C)\C2=CC(=CC=C2)O)/C3=CC=CC=C3

IUPAC name: 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol

Also known as: Droloxifene, Droloxifeno, E-droloxifene, Fk-435, K-060, K-21060E, K060, K060E, Droloxifen, DROLOXIFENE, SCHEMBL4843

Parent form; salt/anhydrous children: CHEMBL2105786

Patent coverage: 8,319 distinct patent families (37,620 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 37,618 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).